Design and development of liquisolid compact of candesartan cilexetil to enhance dissolution

Abstract

BackgroundCandesartan cilexetil is an angiotensin-II receptor antagonist used for the treatment of hypertension. It is hydrophobic drug which belongs to BCS class II and its half life is 5.1 h with 15–40% bioavailability. Attempt had made to investigate the use of liquisolid technique in improving the dissolution of candesartan cilexetil in a solid dosage form. MethodsThe liquisolid tablets were formulated by using Tween 80, as liquid vehicle, microcrystalline cellulose as a carrier material, silica as a coating material and sodium starch glycolate used as a superdisintegrant. The new mathematical model and 32 full factorial design was utilized to formulate various liquisolid powder systems. Result and discussionAll prepared liquisolid batches were subjected to, weight variation, drug content uniformity, hardness, friability test, disintegration test and dissolution tests. Liquisolid system is also tested for DSC, XRD and IR .All the tested liquisolid tablet formulations showed higher drug dissolution than the conventional, directly compressed tablet. ConclusionDSC and XRD study suggested loss of candesartan cilexetil crystallinity upon liquisolid formulation which was further confirmed by SEM, it indicates that drug is held within the powder substrate in a solubilized, almost molecularly dispersed state, which lead to the enhanced drug dissolution properties.